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The use of bone marrow, umbilical cord and other adult stem cells for 
the treatment of various conditions (mostly haematological) is familiar 
to SAMJ readers, as are the scientific and ethical debates surrounding 
the potential use of human embryonic stem (hES) cells for tissue 
repair.1,2 In the specialist medical and scientific literature, however, it is 
a new class of stem cells, induced pluripotent stem (iPS) cells, that are 
causing the greatest excitement of late, and with reason.
Human iPS cells are somatic (diploid) cells, obtained by relatively 
non-invasive procedures (e.g. skin biopsy), that have been genetically 
‘induced’ to revert back to an embryonic stem-cell-like state. The term 
‘pluripotent’ refers to a cell’s ability to differentiate into any cell type in 
the body. Both iPS and hES cells are pluripotent. To turn a somatic cell 
into an iPS cell, simply stated, a very small skin biopsy is taken from 
a patient, a skin fibroblast cell culture is established in vitro, and the 
fibroblast is reprogrammed into an iPS cell. These immortal iPS cells 
can be grown en masse in vitro and differentiated into the particular 
cell type required for therapeutic or non-therapeutic purposes (Fig. 1). 
The key advantage of iPS cells over other stem cells is that they are 
patient-specific (and therefore immuno-compatible) and can be grown 
in infinite amounts. Moreover, they are not dogged by the ethical and 
religious controversies associated with hES cells, yet still have the same 
properties as hES cells. They also offer the possibility of conducting 
‘clinical-trials-in-the-dish’, providing a platform for drug screening, 
disease modelling and gene/cell therapy in pre-clinical studies.3,4
How are iPS cells made?
When cell differentiation occurs, the cell follows a process of changes 
in gene activity whereby embryonic-specific genes are inactivated 
and differentiation-specific genes are activated. The end result of 
this differentiation ‘programme’ is a specialised cell of one type or 
another (e.g. cardiac muscle cells or neurons). To ‘reprogramme’ a fully 
differentiated adult cell into an iPS cell is surprisingly straightforward – 
all that is needed is reactivation of the embryonic regulatory genes  and 
inactivation of the differentiation-specific genes. 
This was achieved in ground-breaking studies in 2006/7 by Takahashi 
and Yamanaka, who showed that the ectopic expression of four key 
embryonic regulatory genes (Oct3/4, Sox2, Klf4 and c-Myc) reactivates 
endogenous pluripotency genes in mouse and human fibroblasts.5,6 
These achievements won Yamanaka the 2012 Nobel Prize in Medicine. 
iPS cells for therapeutic use
Many reports and reviews on the production of iPS cells and their 
possible therapeutic potential have rapidly followed. iPS cells have been 
derived from a wide range of cell types and differentiated into an equally 
broad range of cell types involved in neurological, haematological, 
metabolic, cardiac and vascular, pancreatic and hepatic conditions.7-10 
Conditions in which treatment using iPS cells is being considered and 
actively pursued include genetic and acquired degenerative diseases, 
amelioration of the effects of ageing, and novel treatments for some of 
South Africa (SA)’s most serious infectious diseases. The true potential 
of iPS cells has yet to be established. Many concerns about their 
derivation must be addressed before they are ready for therapeutic use.
iPS cells and disease-in-the-dish models
Disease-in-the-dish studies have progressed much further. A broad 
spectrum of both monogenic diseases such as Duchenne’s muscular 
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Fig. 1. Medical and research potential of iPS technology. The process of 
reprogramming a somatic cell into an iPS cell and back to a differentiated cell 
requires relatively few manipulations. Reprogramming requires the uptake of 
reprogramming factors, such as Oct3/4, Sox2, Klf4 and c-Myc, by the somatic 
cell. This leads to a number of changes, including changes in physical structure, 
gene expression and proliferative ability. Genes functional in the somatic cell 
get switched off and the endogenous stem cell-associated genes are switched 
on. All of these changes form part of the induction of pluripotency, which 
leads to the generation of embryonic stem-cell-like iPS cells and formation 
of iPS cell colonies. The differentiation process requires the introduction of 
factors required to force the iPS cells along a lineage of a specific target cell 
type. The target cells can be used to create disease models in a cell culture dish, 
for disease-specific drug screening, genetic manipulations to repair disease-
causing mutations, or to bulk up cells for transplantation into the cell donor.
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dystrophy and Huntington’s disease, as well as complex adult-onset 
diseases (e.g. Parkinson’s, Alzheimer’s and schizophrenia, to name 
a few) have been modelled in vitro.9,10 How effective iPS cell-derived 
disease models are at reproducing the disease cellular phenotype, 
and at demonstrating the effects of drugs, is more easily recognised 
in early-onset diseases that have a strong genetic component and an 
identifiable disease-associated cellular phenotype. This is exemplified 
by a patient-derived iPS cell model for familial dysautonomia, which 
was used to show that the disease phenotype could be partially 
normalised by a plant hormone.11
An example of the medical application of iPS cell technology was 
demonstrated by Itzhaki et al.,12 who used an iPS-model for Long-
QT syndrome to identify complex effects of cardiotoxic drugs and 
protective pharmacological agents for disease sufferers.
Our studies of spinocerebellar ataxia 7 (SCA7), a late-onset 
neurodegenerative genetic disease found almost exclusively in families 
of black origin in SA, exemplify our use of iPS cell technology in 
disease modelling.13 The development of effective therapies for a group 
of genetic conditions known as the polyglutamine (polyQ) diseases 
is particularly relevant to SA populations where, for example, the 
frequencies of spinocerebellar ataxia type 1 (SCA1) and type 7 (SCA7) 
are among the highest in the world.14 
To date, our research has been primarily focused on the study of 
the SCA7 protein in transfected neuronal cell lines and transgenic 
mouse models.15,16A unique clinical feature of this condition is loss of 
vision associated with retinal degeneration (in particular the macula), 
the aetiology of which is unknown. To explore the cause of retinal cell 
death in SCA7 patients, we have derived iPS cells from skin biopsies 
following standard protocols (UCT HREC ref. 460/2010 and 434/2011, 
both renewed in 2012 until 2013) and carried out in accordance with 
national stem cell regulations (promulgation in progress), cultured 
them en masse, and have successfully differentiated them into retinal 
pigment epithelial cells and neuronal cells.16 With these unique cells 
in hand, we are now able to investigate the cellular vulnerabilities 
conferred on the cells of the eyes of our South African SCA7 patients, 
and have a powerful tool to explore models of cell interactions and cell 
death. In addition, we are able to examine and observe patient-specific 
drug treatments that might eventually delay the onset of blindness 
arising as a result of cell death in South African SCA7 patients.
Risks, limitations and challenges
Despite the evident success of iPS cell technology to date, the field has 
been complicated by a number of challenges, not least that Takahashi 
and Yamanaka and many others used viral vectors (retrovirus, 
lentivirus) to transport the reprogramming genes into the somatic 
cells.5,6 The risk is that the viral integration itself could result in rogue 
cells with tumorigenic propensities. This is of particular concern as the 
technology rapidly moves towards clinical application. 
Other methods of delivering reprogramming genes into cells use 
non-integrating agents of induction, such as the deleted persistent 
variant of the Sendai virus (SeVdp), viral-free non-integration 
approaches, proteins, mRNA and miRNA.17-22 Most non-integrating 
methods, however, result in reduced reprogramming efficiencies.23 
In our experience, induction with the Sendai virus has been most 
successful following our previous utilisation of retroviruses. Following 
these challenges, researchers have included rigorous quality-control 
steps to test the purity and integrity of iPS cells before differentiation.
Conclusions
Creating cells takes time and a great deal of care, and is not suitable 
for acute conditions. However, the rise of large-scale bio-repositories 
may yet deal with this limitation. Technical research challenges and 
ethical controversies have delayed the progress of iPS cell technology 
and narrowed the scope of iPS cell banks to research projects, rather 
than treatment. This has resulted in recruiting iPS cells from patients 
and their family members rather than from larger population samples. 
However, in an unprecedented move, Yamanaka plans to create a bank 
of stem cells from fetal cord blood for therapeutic use in Japan, shifting 
the potential of iPS cell technology to new heights.24
It is vital that the SA medical and scientific fraternity become 
familiar with iPS cell technology – a reality that has demonstrated 
evidence of proof-of-principle.10 Researchers and clinical practitioners 
should be encouraged to communicate with accredited stem cell or 
tissue culture laboratories, and should inform patients about potential 
iPS cell prospects. Bearing in mind the variation of disease phenotypes 
and clinical manifestations, it is important to build up an SA bank 
of patient-derived iPS cells from different patients diagnosed with 
the same disease for a more accurate representation of underlying 
pathology. There is no doubt that iPS cell technology and patient-
derived disease-in-a-dish models have the potential: (i) to exponentially 
increase our understanding of underlying disease mechanisms and 
cellular phenotype responses to drug treatments; and (ii) to introduce 
novel treatments for some of SA’s most serious diseases.
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